Common antibiotic linked to higher risk of death in adults, major study finds, tell me about this news in (https://www.foxnews.com/health/common-antibiotic-linked-higher-risk-death-adults-major-study-finds)

The article reports on a global study published in JAMA Network Open that examined cefepime, a widely used broad-spectrum antibiotic administered intravenously in hospital settings for serious conditions like pneumonia, urinary tract infections (UTIs), skin infections, and febrile neutropenia.Key takeaways from the report include:

• Study Scope: Researchers reviewed 110 randomized clinical trials covering more than 22,000 patients who received either cefepime or another beta-lactam antibiotic (such as other cephalosporins or penicillins).
• Mortality Findings: Across all trials, 6.6% of patients treated with cefepime (778 out of 11,726) died from any cause within roughly 30 days, compared to 6.2% in patients receiving alternative antibiotics.
• Statistical Probability: Using a Bayesian meta-analysis, the researchers calculated a 94.4% probability that cefepime was associated with higher all-cause mortality compared to alternatives. That probability rose to 98.6% when restricted to 73 peer-reviewed published trials.
• Most Affected Groups: The association was more noticeable in adults than in children, and the risk was most pronounced among patients treated for febrile neutropenia (fever accompanied by critically low white blood cell counts).
• Potential Causes: Finding the proper dosage for cefepime can be difficult. The authors noted that suboptimal outcomes could stem from underdosing (failing to clear severe infections) or overdosing (triggering neurotoxicity, such as confusion, altered mental state, or seizures, especially in older patients or those with kidney impairment).
• Important Caveats: The study showed an association, not definitive proof that cefepime directly caused the deaths. In addition, the analyzed trials spanned several decades and varied in dosing regimens and patient conditions. The researchers did not recommend stopping use of the drug, but emphasized the need for updated safety guidance and careful, individualized dosing.